Brief: Schrödinger Reports New Preclinical Data Supporting Advancement Of Its Wee1 Inhibitor Program

Schrodinger

12/04/2022 12:35

April 12 (Reuters) - Schrodinger Inc  SDGR.O :
    * SCHRÖDINGER REPORTS NEW PRECLINICAL DATA SUPPORTING
ADVANCEMENT
OF ITS WEE1 INHIBITOR PROGRAM AT AMERICAN ASSOCIATION OF CANCER
RESEARCH 2022 ANNUAL MEETING
    * SCHRODINGER INC - HIGHLY SELECTIVE AND
STRUCTURALLY-DISTINCT
WEE1 INHIBITORS DEMONSTRATE STRONG ANTI-TUMOR ACTIVITY IN TUMOR
MODELS
    * SCHRODINGER INC - ON TRACK TO SELECT A WEE1 DEVELOPMENT
CANDIDATE IN 2022

Source text for Eikon:  ID:nBwn4ld8a 
Further company coverage:  SDGR.O 

 ((reuters.briefs@thomsonreuters.com;))